… supported dacomitinib to be an ideal first line therapy for … of dacomitinib remains to be
determined. Our article will make a comprehensive review for the clinical application of dacomitinib …

… systemic anti-cancer therapy in the second line, although a small … of dacomitinib and
subsequent systemic anti-cancer … dacomitinib in patients with EGFR-positive NSCLC in Japan. …

… First-line dacomitinib was associated with significant prolongation of PFS and improved
OS … The AE profiles of dacomitinib and gefitinib in Asian patients were consistent with the …

… Finally, an international, multicenter, phase II trial is assessing the safety and efficacy of
dacomitinib, with or without dose titration, as first line for advanced NSCLC with EGFR activating …

… cell lung cancer (NSCLC). Areas covered: We review the efficacy and safety of dacomitinib
as a first-line … , and evaluate the activity of dacomitinib against brain metastases. Additionally, …

… The updated data with a median OS of 34.1 months demonstrate its superior efficacy over
gefitinib first line. However, the clinical benefit must be carefully balanced with the increased …

… front-line TKI and dacomitinib resulted in a longer PFS. … -line dacomitinib was active for
patients with NSCLC harboring rare mutations, and it also indicated the feasibility of dacomitinib …

… In conclusion, the OS benefit from first-line treatment with dacomitinib versus gefitinib
was maintained after extended follow-up in patients with advanced NSCLC with EGFR-activating …

… trials of dacomitinib. We particularly discuss the mechanism of action of dacomitinib and its
clinical efficacy and toxicity as a novel, first-line therapeutic option for EGFR-mutated NSCLC. …

… In summary, dacomitinib provides a new treatment option for the first-line treatment of patients
with EGFR mutation-positive advanced NSCLC. Most ADRs related to dacomitinib can be …